A dual-regulated oncolytic adenovirus expressing interleukin-24 sensitizes melanoma cells to temozolomide via the induction of apoptosis

被引：18

作者：

Jiang, Guan ^{[1
]}

Jiang, Ai-Jun ^{[1
]}

Cheng, Qian ^{[1
]}

Tian, Hui ^{[1
]}

Li, Lian-Tao ^{[1
]}

Zheng, Jun-Nian ^{[1
]}

机构：

[1] Xuzhou Med Coll, Jiangsu Key Lab Biol Canc Therapy, Xuzhou 221002, Peoples R China

来源：

TUMOR BIOLOGY | 2013年 / 34卷 / 02期

基金：

中国国家自然科学基金;

关键词：

Melanoma; Oncolytic adenoviruses; Interleukin-24; Temozolomide; Apoptosis; ANTITUMOR-ACTIVITY; BREAST-CANCER; LUNG-CANCER; VIROTHERAPY; REPLICATION; RESISTANCE; ALKYLTRANSFERASE; ACTIVATION; VECTORS; MUTANT;

D O I：

10.1007/s13277-013-0701-7

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Malignant melanoma is one of the most lethal and aggressive human malignancies. Suppressed apoptosis and extraordinary invasiveness are the distinctive features that contribute to malignant melanoma. The alkylating agent temozolomide (TMZ) is one of the most effective single chemotherapeutic agents for patients with malignant melanoma, but resistance develops quickly and with high frequency. We constructed a dual-regulated oncolytic adenovirus expressing interleukin 24 (IL-24) gene (Ki67-ZD55-IL-24) by utilizing the Ki67 promoter to replace the native viral promoter of E1A gene. We investigated whether a combination of Ki67-ZD55-IL-24-mediated gene virotherapy and chemotherapy using TMZ produces increased cytotoxicity against human melanoma cells via the induction of apoptosis. Our data indicate that this novel strategy thus holds promising potentials for further developing an effective approach to treat malignant melanoma.

引用

页码：1263 / 1271

页数：9